Patents by Inventor Erkki Ruoslahti

Erkki Ruoslahti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130058993
    Abstract: Disclosed are compositions and methods useful for treating wounded, injured, and inflamed tissue. The compositions and methods are based on peptide sequences, such as CAR peptides and truncated CAR peptides, that are selectively targeted to wounded tissue and are internalized by a cell, penetrate tissue, or both. The disclosed peptides promote and enhance wound healing.
    Type: Application
    Filed: February 28, 2012
    Publication date: March 7, 2013
    Inventors: Erkki Ruoslahti, Tero Jarvinen
  • Patent number: 8367621
    Abstract: Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tissue experiencing angiogenesis or to cells or tissue expressing ?v integrins.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: February 5, 2013
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara
  • Publication number: 20120219502
    Abstract: Disclosed are compositions and methods useful for targeting gC1q/p32 receptors. The disclosed targeting is useful for delivering therapeutic and detectable agents to cancerous cells, and to areas of inflammation.
    Type: Application
    Filed: April 17, 2012
    Publication date: August 30, 2012
    Inventors: Erkki Ruoslahti, Valentina Fogal
  • Publication number: 20120201753
    Abstract: Disclosed are compositions and methods useful for targeting regenerating tissue, wounds, and tumors. The compositions and methods are based on peptide sequences that selectively bind to and home to regenerating tissue, wound sites, and tumors in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to regenerating tissue, wound sites, and tumors in animals.
    Type: Application
    Filed: April 19, 2012
    Publication date: August 9, 2012
    Inventors: Erkki Ruoslahti, Tero Jarvinen
  • Patent number: 8188220
    Abstract: Disclosed are compositions and methods useful for targeting regenerating tissue, wounds, and tumors. The compositions and methods are based on peptide sequences that selectively bind to and home to regenerating tissue, wound sites, and tumors in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to regenerating tissue, wound sites, and tumors in animals.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: May 29, 2012
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Tero Jarvinen
  • Patent number: 8188221
    Abstract: The present invention relates to a peptide, which specifically homes to the intracranial, early stage astrocytoma model that grows as islets and harbors co-opted tumor vessels in the brain. The peptide finds its use in targeted delivery of therapeutic substances to invasive brain cancer or metastatic brain lesions as such and in combination with conventional therapies, such as surgery and radiation, and anti-angiogenic therapies, and as a tool in diagnosis of, e.g., invasive brain cancer or metastatic brain lesions.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: May 29, 2012
    Assignees: Burnham Institute for Medical Research, The Regents of the University of California, UCSF
    Inventors: Pirjo Laakkonen, Erkki Ruoslahti, Gabriele Bergers
  • Patent number: 8188051
    Abstract: Metadherin, a protein that controls metastasis, and variants of metadherin are described. DNA sequences encoding the same and methods of production are described. Therapies involving the application of metadherin, binding agents that bind to metadherin, such as antibodies, and expression modulating agents, such as siRNA, are described. The use of metadherin or metadherin variants for delivering desired substances to particular lung tissue is described. A method of diagnosing metastatic cells based on the presence of metadherin is described.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: May 29, 2012
    Assignee: The Burnham Institute
    Inventors: Erkki Ruoslahti, Darren M. Brown
  • Publication number: 20120121501
    Abstract: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.
    Type: Application
    Filed: October 18, 2011
    Publication date: May 17, 2012
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Erkki Ruoslahti, Kimmo Porkka, Sven Christian
  • Patent number: 8178104
    Abstract: Disclosed are compositions and methods useful for targeting gC1q/p32 receptors. The disclosed targeting is useful for delivering therapeutic and detectable agents to cancerous cells, and to areas of inflammation.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: May 15, 2012
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Valentina Fogal
  • Publication number: 20120034164
    Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences, such as truncated CAR peptides, that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.
    Type: Application
    Filed: September 1, 2011
    Publication date: February 9, 2012
    Inventors: Erkki Ruoslahti, Tero Järvinen, Masanobu Komatsu
  • Publication number: 20120014974
    Abstract: The present invention provides a method of identifying an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. The method is practiced by contacting a Bit1 polypeptide, or active fragment thereof, and an AES polypeptide, or active fragment thereof, with an agent under conditions that allow the Bit1 polypeptide or active fragment thereof to associate with the AES polypeptide or active fragment thereof; and detecting an altered association of the Bit1 polypeptide or active fragment thereof and the AES polypeptide or active fragment thereof, where an altered association indicates that the agent is an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. Such an effective agent can modulate apoptosis and can be a useful therapeutic agent.
    Type: Application
    Filed: June 6, 2011
    Publication date: January 19, 2012
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Yiwen Jan, Michelle Matter, Jih-tung Pai, Erkki Ruoslahti
  • Patent number: 8048983
    Abstract: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: November 1, 2011
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Kimmo Porkka, Sven Christian
  • Publication number: 20110262347
    Abstract: Disclosed are compositions and methods related to multivalent compositions targeted to cells and tissues. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
    Type: Application
    Filed: April 8, 2011
    Publication date: October 27, 2011
    Inventors: Erkki Ruoslahti, Lilach Agemy, Dinorah Friedmann-Morviniski, Venkata Ramana Kotamraju, Kazuki Sugahara, Inder Verma
  • Patent number: 8017326
    Abstract: The present invention provides a method of identifying an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. The method is practiced by contacting a Bit1 polypeptide, or active fragment thereof, and an AES polypeptide, or active fragment thereof, with an agent under conditions that allow the Bit1 polypeptide or active fragment thereof to associate with the AES polypeptide or active fragment thereof; and detecting an altered association of the Bit1 polypeptide or active fragment thereof and the AES polypeptide or active fragment thereof, where an altered association indicates that the agent is an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. Such an effective agent can modulate apoptosis and can be a useful therapeutic agent.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: September 13, 2011
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Yiwen Jan, Michelle Matter, Jih-Tung Pai, Erkki Ruoslahti
  • Publication number: 20110212162
    Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
    Type: Application
    Filed: February 10, 2011
    Publication date: September 1, 2011
    Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
  • Publication number: 20110165064
    Abstract: Disclosed are compositions and methods related to clot-binding compounds. For example, disclosed are compositions comprising a surface molecule and at least one modified clot-binding compound. The modified clot-binding compound can selectively bind to clotted plasma protein, wherein the composition causes clotting and amplifies the accumulation of the composition in tumors. The modified clot-binding compound can enhance the clotting in tumors compared to its unmodified derivative. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
    Type: Application
    Filed: December 20, 2010
    Publication date: July 7, 2011
    Inventors: Erkki Ruoslahti, Lilach Agemy, Venkata Ramana Kotamraju
  • Publication number: 20110130342
    Abstract: The present invention relates to a peptide, which specifically homes to the intracranial, early stage astrocytoma model that grows as islets and harbors co-opted tumor vessels in the brain. The peptide finds its use in targeted delivery of therapeutic substances to invasive brain cancer or metastatic brain lesions as such and in combination with conventional therapies, such as surgery and radiation, and anti-angiogenic therapies, and as a tool in diagnosis of, e.g., invasive brain cancer or metastatic brain lesions.
    Type: Application
    Filed: May 8, 2009
    Publication date: June 2, 2011
    Applicant: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Pirjo Laakkonen, Erkki Ruoslahti, Gabriele Bergers
  • Publication number: 20110081293
    Abstract: Disclosed are compositions and methods related to clot-binding head groups. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
    Type: Application
    Filed: September 30, 2010
    Publication date: April 7, 2011
    Applicants: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: ERKKI RUOSLAHTI, DAVID PETERS, MATTHEW TIRRELL, MARK KASTANTIN
  • Patent number: 7919466
    Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: April 5, 2011
    Assignees: The Regents of the University of California, Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
  • Publication number: 20110002848
    Abstract: The present invention provides a conjugate that contains a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of pre-malignant dysplastic skin and which includes the amino acid sequence SRPRR (SEQ ID NO: 1) or a conservative variant or peptidomimetic thereof. The present invention further provides a conjugate containing a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of malignant skin and which includes the amino acid sequence CGKRK (SEQ ID NO: 6) or the amino acid sequence CDTRL (SEQ ID NO: 7), or a conservative variant or peptidomimetic of one of these sequences.
    Type: Application
    Filed: March 26, 2010
    Publication date: January 6, 2011
    Applicants: BURNHAM INSTITUTE FOR MEDICAL RESEARCH, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: DOUGLAS HANAHAN, ERKKI RUOSLAHTI